JOMMI, CLAUDIO
JOMMI, CLAUDIO
Accordi di managed market entry (risk-sharing): razionale e tendenze evolutive nel SSN
2012 Jommi, Claudio
An EQ-5D-5L value set for Italy using videoconferencing interviews and feasibility of a new mode of administration
2022 Finch, Aureliano Paolo; Meregaglia, Michela; Ciani, Oriana; Roudijk, Bram; Jommi, Claudio
An introduction to economic evaluation of health care programs
2017 Jommi, Claudio
Analisi di impatto sul budget di WatchmanTM, dispositivo per la prevenzione tromboembolica nei pazienti con fibrillazione atriale
2013 Jommi, Claudio; A., Iorio; L., Crippa; A., Gelera; G., Senatore
Biosimilari
2010 Jommi, Claudio
Budget impact analysis of rituximab biosimilar in Italy from the hospital and payer perspectives
2018 Rognoni, Carla; Bertolani, Arianna; Jommi, Claudio
CAR T-cell therapies in Italy: patient access barriers and recommendations for health system solutions
2022 Jommi, Claudio; Bramanti, Stefania; Pani, Marcello; Ghirardini, Alessandro; Santoro, Armando
Clinical management of chronic Kidney disease patients in Italy: results from the IRIDE study
2018 Cozzolino, Mario; Bolasco, Piergiorgio; Ronco, Claudio; Conte, Giuseppe; Menè, Paolo; Cristina Mereu, Maria; Di Luca, Marina; Roccatello, Dario; Rosati, Alberto; Jommi, Claudio; Maria Costanzo, Anna; Gualberti, Giuliana; di Luzio Paparatti, Umberto; Remuzzi, Giuseppe
Cost of implementing CAR-T activity and managing CAR-T patients: an exploratory study
2024 Cavallo, Maria Caterina; Cavazza, Marianna; Bonifazi, Francesca; Casadei, Beatrice; Cutini, Ilaria; Tonietti, Barbara; Saccardi, Riccardo; Zinzani, Pierluigi; Jommi, Claudio
Cost-effectiveness and net monetary benefit of durvalumab consolidation therapy versus no consolidation therapy after chemoradiotherapy in stage III non–small cell lung cancer in the Italian National Health Service
2020 Armeni, Patrizio; Borsoi, Ludovica; Fornaro, Giulia; Jommi, Claudio; Grossi, Francesco; Costa, Francesco